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How best to help kids lose weight
An aggressive approach—paired with medication for older 
kids—can help obese youngsters successfully slim down. 
PRACTICE CHANGER
Screen children and adolescents for obesity 
and off er them multifaceted weight loss inter-
ventions, based on new evidence (and a recent 
US Preventive Services Task Force [USPSTF] 
recommendation) of their eff ectiveness. Con-
sider adding a weight loss medication as fur-
ther help for adolescents.1,2 
STRENGTH OF RECOMMENDATION 
A: Based on a systematic review of 23 ran-
domized and 2 nonrandomized controlled 
trials. 
Whitlock E, O’Connor E, Williams S, et al. Eff ectiveness of weight man-
agement interventions in children: a targeted systematic review for the 
USPSTF. Pediatrics. 2010;125;e396-e418.
ILLUSTRATIVE CASE 
A 10-year-old boy comes in with his mother 
for a well-child check-up. His BMI is 40 kg/m2—
above the 99th percentile for his age and 
up from 37 a year ago. His blood pressure is 
120/84 mm Hg. What treatment, if any, should 
you offer for his obesity?
Childhood obesity is a global epidemic. In the United States, 19.6% of children ages 6 through 11 and 18.1% of 12- to 
19-year-olds are obese, a 3-fold increase in 
the last 30 years.3 Without intervention, most 
obese adolescents will become obese adults, 
threatening to reverse the progress in slowing 
cardiovascular morbidity and mortality that 
has occurred over the past few decades.3 
Obese kids get adult diseases 
Obesity is a risk factor for a variety of chronic 
conditions, including cardiovascular disease, 
cerebrovascular disease, and arthritis. Severe 
obesity is also associated with higher mortal-
ity rates.4 Unfortunately, these comorbidities 
are not limited to adulthood. 
“Adult” diseases, such as obstructive 
sleep apnea, dyslipidemia, and type 2 diabe-
tes, are increasingly seen in children and ado-
lescents.1 Nutritional defi cits such as vitamin 
D and iron defi ciency are often seen in obese 
children, as well.5 Th ere are also psychological 
ramifi cations of childhood obesity, including 
social isolation and depression.6 
Th e USPSTF recently upgraded its rec-
ommendation regarding obesity screening in 
children ages 6 and older from I (insuffi  cient 
evidence) to B (a positive grade based on high 
or moderate certainty of the benefi t of the in-
tervention), citing new evidence in favor of 
screening and treating or referring children 
when appropriate.2 Th e systematic review we 
report on here, which formed the basis for the 
USPSTF’s upgrade, focused on management 
options for children identifi ed as overweight 
or obese. 
STUDY SUMMARY
Intense, comprehensive efforts pay off
Th is systematic review1 included studies of 
children ages 4 to 18 years who were overweight 
(defi ned as a body mass index [BMI] in the 85th 
to 94th percentile for age and sex) or obese 
(either a BMI at or above the 95th percentile 
for age and sex or a BMI >30 kg/m2). Th e re-
searchers found 25 trials—15 of behavioral 
interventions alone and 10 that combined be-
havioral and pharmacologic interventions—
that met their criteria: Th e studies focused on 
weight loss and/or maintenance, reported out-
comes ≥6 months from baseline, and were con-
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ducted (or feasible) in a primary care setting. 
Behavioral interventions were catego-
rized by treatment intensity (as measured by 
hours of contact, which ranged from <10 hours 
to >75) and comprehensiveness (including 
nutritional counseling, physical activity coun-
seling or participation, and counseling on 
behavioral management techniques). Weight 
outcomes were categorized as short-term 
(6-12 months since treatment initiation) or 
maintenance (≥12 months after the end of ac-
tive treatment). 
Th e 15 behavioral intervention trials in-
cluded 1258 children ages 4 to 18 years, most 
of whom were obese. Most trials were small 
and reported high retention rates. All had 
benefi cial eff ects on weight in the intervention 
group compared with the controls, but not all 
changes were statistically signifi cant. Higher 
intensity and more comprehensive programs 
had better outcomes. 
❚ The largest effects were in 3 moder-
ate- to high-intensity, comprehensive weight 
management programs with ≥26 hours of con-
tact. Th ese 3 trials demonstrated a diff erence 
in BMI of 1.9 to 3.3 in the intervention groups 
at 12 months compared with the controls. (A 
3.3 diff erence in BMI is equal to approximately 
13 lb in an 8-year-old and 17 lb in a 12-year-old.)
Four behavioral intervention studies re-
ported outcomes ≥12 months after completing 
the intervention (range 15-48 months). Th ree 
of the 4 reported continued benefi cial eff ects 
on weight after the active treatment period, 
but the eff ects were markedly attenuated. 
❚ The only adverse effect reported in the 
trials of behavioral interventions was the inju-
ry rate among children in an exercise program, 
but it was minimal: One fracture was reported, 
vs no injuries for the controls. No diff erences 
were reported in height, eating disorders, or 
depression. However, fewer than half of the 
behavioral intervention trials reported on ad-
verse eff ects.
Weight loss drugs have modest effects 
Ten trials combining pharmacologic and be-
havioral interventions involved a total of 1294 
obese adolescents ages 12 to 19. All evalu-
ated short-term weight loss eff ects of either 
sibutramine (10-15 mg/d) or orlistat (120 mg 
tid). Trials ranged from 3 to 12 months. Par-
ticipants in both the control and intervention 
groups received behavioral counseling. 
Th e trials all favored the treatment 
groups, although not all of the results were sta-
tistically signifi cant. Trials of longer duration 
(12 months) had more favorable results than 
those lasting 6 months. 
Th e largest sibutramine trial (n=498) re-
ported a mean BMI reduction of 2.9 in the 
treatment group, compared with a reduction 
of 0.3 in the control group (P<.001). Th is cor-
responds to an average weight loss of 14 lb in 
the intervention group, vs 4.2 lb in the control 
group, after 12 months. 
Th e largest orlistat trial (n=539) reported 
a mean BMI reduction in the treatment group 
of 0.6, vs 0.3 in the control group (P<.001)—an 
average weight loss of 4.2 lb in the interven-
tion group, compared with 2.1 lb among the 
controls after 12 months. None of the trials 
evaluated weight change after cessation of the 
study drug, and none compared orlistat with 
sibutramine.
Adverse eff ects in the sibutramine-
treated patients were primarily cardiovascular 
and gastrointestinal. Cardiovascular eff ects 
included tachycardia and increases in sys-
tolic and diastolic blood pressure. Th e diff er-
ences between the intervention and control 
groups were small, and no diff erences were 
observed in discontinuation rates caused by 
adverse events. Nor were diff erences reported 
in growth and maturation between the inter-
vention and control groups. 
Adverse eff ects in the orlistat-treated 
patients were also low and similar in the inter-
vention and control groups. Gastrointestinal 
eff ects were common. Th e number needed to 
harm (NNH) for fatty or oily stools was 2,4 and 
the NNH for fecal incontinence was 12.5
WHAT’S NEW?
Clinicians treating obese kids
have cause for optimism 
Although the trials included in this review 
were heterogeneous and many were small, 
this systematic review provides evidence that 
intensive, comprehensive behavioral weight 
loss interventions for obese children can be 
eff ective up to 12 months after the conclusion 
of the program. Family physicians should con-
INSTANT 
POLL 
QUESTION
Which of the following 
interventions best 
describes what you 
off er to obese children 
and adolescents?
❑  Counseling on diet 
and exercise 
❑  Counseling and 
intensive follow-up
❑  Referral to a formal 
weight loss program
❑  A recommendation 
to patients (and 
parents) to lose 
weight
❑  None 
Go to jfponline.com
and take our instant poll 
sider referring obese children and adolescents 
to such programs—or fi nding ways to provide 
supportive strategies themselves. 
Sibutramine and orlistat may be helpful 
in the context of comprehensive, intensive 
behavioral interventions, although there is no 
follow-up data to demonstrate long-term safe-
ty and weight maintenance after the medica-
tion is stopped.
CAVEATS
Little is known about
long-term safety of the drugs
Th ere have been few randomized trials of phar-
macologic interventions in adolescents and 
none evaluating weight maintenance after 12 
months (or discontinuation of treatment), or 
assessing long-term safety of the medication. 
Sibutramine is not approved by the US 
Food and Drug Administration (FDA) for use in 
children or adolescents.7 Orlistat is currently ap-
proved only for individuals over the age of 12.8 
In January 2010, an additional contraindi-
cation was added to the sibutramine drug label, 
stating that it is not to be used in patients with 
a history of cardiovascular disease.9 And the 
FDA is currently investigating a rare associa-
tion between orlistat and liver injury, although 
no conclusions have been released.10 Children 
and adolescents are particularly vulnerable 
to long-term side eff ects, given their relatively 
young age at the time of drug initiation, so we 
urge caution with the use of these drugs in this 
patient population. 
CHALLENGES TO IMPLEMENTATION 
Intensive approach
may be hard to reproduce
Implementation of high-intensity compre-
hensive interventions for obese children faces 
a number of roadblocks, including limited 
availability of programs, cost, and reimburse-
ment. Most of the intensive interventions 
in these trials took place in specialty centers 
rather than in primary care offi  ces. Replicat-
ing them could require a referral—or signifi -
cant resources within the primary care setting 
itself. Yet many, if not most, insurance poli-
cies still do not cover such extensive lifestyle 
interventions. (For information on weight loss 
interventions for adults, see “Weight loss strat-
egies that really work” on page 378). 
None of these trials reported on cost or cost 
eff ectiveness. Despite the considerable cost of a 
comprehensive obesity management program, 
however, a successful weight-maintenance 
model could be a worthwhile investment in 
long-term health. 
Lastly, the results of this trial should not 
negate the importance of obesity prevention ef-
forts by parents, who are in the best position to 
reverse the childhood obesity epidemic.11      JFP
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Family physicians 
should consider 
referring obese 
children and 
adolescents 
to weight 
management 
programs—or 
fi nding ways to 
provide 
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themselves.
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